Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy

Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy
Recruiting
18 years - 99 years
All
Phase 2
130 participants needed
1 Location

Brief description of study

The research study is being conducted to evaluate a new imaging technique for detecting the response of hepatocellular carcinoma (HCC) to locoregional or systemic therapy. Locoregional therapies or LRT are called Transarterial Chemoembolization or TACE, Transarterial Radioembolization or TARE and Microwave Ablation or MWA. Systemic therapies or ST are therapy drugs that spread throughout the body to treat cancer cells. They include chemotherapy, hormonal therapy, targeted drugs, and immunotherapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hepatocellular Carcinoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older, at least one tumor meeting LI-RADS 5 criteria on imaging, and referred to undergo LRT or receive ST.

Updated on 04 Aug 2024. Study ID: 834798

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center